Fundraising Fox
ARCH Venture Partners
Venture capitalActively deployingChicago · Seed–Growth · 49 people tracked
Also known as Arch Asset Management Inc · ARCH Venture · ARCH VENTURE CORP · ARCH VENTURE MANAGEMENT LLC
Find your way into ARCH Venture Partners
Each arrow is one introduction. Sign up to fill in the first one.
Ask Christina Isacson to introduce you to Carol Suh
You →Christina · together at Magenta Therapeutics →Carol
Ask Jamie Chen to introduce you to Robert Nelsen
You →Jamie · together at RIPPL Care →Robert
Ask Sam Okafor to introduce you to Clinton Bybee
You →Sam · together at Voxel8: Multi-Material Digital Manufacturing →Clinton
- Kristina Burow85 people can intro you
- Keith Crandell65 people can intro you
- Steve Gillis52 people can intro you
Sign up to find every way you can get introduced to ARCH Venture Partners
- Your email: who you already know at ARCH Venture Partners, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the ARCH Venture Partners team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
ARCH Venture Partners takes a contrarian, bold approach to venture investing, founding and building companies around revolutionary science and technologies intended to improve people's lives. The firm follows the science to identify opportunities and adopts a long-term view when building companies, remaining flexible in its approach and sizing investments in each portfolio company as needed. It leverages an extended network of partners to help companies through their formation stages and support their growth to full potential.
Source: firm website, verified Sep 29, 2026.
Team · 49 people
from the firm's website & public directories
Founder mafia
The ARCH Venture Partners mafia →16 people who came through ARCH Venture Partners went on to found or lead other companies.
What they invest in
from 182 of 231 portfolio companiesBiotech ×147Medical Devices ×72Healthtech ×64Deep Tech ×58AI & Machine Learning ×44Digital Health ×24Advanced Manufacturing ×9Enterprise Software ×9
HQs:United States×152China×3United Kingdom×3India×3Australia×1Switzerland×1
Who they back
founder profiles across 88 portfolio companiesFounding team size:solo founder×332 founders×223 founders×174+ founders×16
Where their founders studiedfrom 71 founders with education data
University of California, Berkeley ×6Harvard University ×5Princeton University ×5Columbia University ×3Columbia University Vagelos College of Physicians and Surgeons ×3The Wharton School ×3University of Colorado Boulder ×3Yale School of Medicine ×3
What their founders studiedfrom 71 founders with field-of-study data
Life Sciences ×30Chemistry ×13Medicine ×9Computer Science ×8Engineering ×8Physics ×7Business & Management ×6Economics ×4
Where their founders worked beforefrom 80 founders with career history
Brigham and Women's Hospital ×5Biotechnology Innovation Organization ×4Harvard Medical School ×4University of California, San Francisco ×4Harvard University ×3Receptos ×3Unity Biotechnology ×3Agilent ×2
47 founders hold a PhD · 7 hold an MBA (of 71 with degree data) · backed the same founder in 2+ companies: 6 founders
Investments · 231 tracked
founders shown can be your intro pathBy year:2026 · 182025 · 172024 · 262023 · 142022 · 212021 · 192020 · 152019 · 72018 · 132017 · 72016 · 42015 · 15191 dated
Prime Medicine develops one-time genetic therapies using Prime Editing, a gene editing technology developed in David R.
BiotechDeep TechHealthtechMedical Devices
Andrew Anzalone(Co-founder and Head of Platform)inDavid Liu(Co-founder)inAllan Reine(Chief Executive Officer)inMohammed Asmal(Chief Medical Officer)inAnn Lee(Chief Technical Officer)inSvetlana Makhni(Chief Financial Officer)in
Co-investorsGV (Google Ventures)Newpath PartnersF-Prime CapitalOUP (Osage University Partners)Samsara BioCapitalArrive+1 more
908 Devices manufactures handheld mass spectrometry and chemical analysis devices for rapid detection in defense, security, and hazardous materials response applications.
Deep TechDefense TechHardwareMedical DevicesBoston, US
Kevin J. Knopp, PhD(CEO & Co-founder)Christopher Brown(Executive Officer)inKevin Knopp(Executive Officer, Director)inJoseph Griffith IV(Executive Officer)
BoardCorey Steffek(Director)
Board seatKeith CrandellKevin Hrusovsky· per SEC Form D
Co-investorsRazor's Edge VenturesUTECAramco VenturesARK Investment ManagementBlackRockCasdin Capital+3 more
Beam Therapeutics develops gene-editing medicines, particularly base editors and precision genome editing technologies, to create lifelong cures for patients with serious genetic diseases.
BiotechDeep TechMedical DevicesCambridge, US
David R. Liu(Founder and Inventor)inJ. Keith Joung(Founder and Inventor)inFeng Zhang(Founder and Inventor)David R. Liu, Ph.D.(Founder and Inventor)J. Keith Joung, M.D., Ph.D.(Founder and Inventor)Feng Zhang, Ph.D.(Founder and Inventor)
Board seatRobert NelsenKristina Burow· per SEC Form D
Co-investorsDreamers VCEight Roads VenturesF-Prime CapitalForesite CapitalGV (Google Ventures)HongShan Capital Group+1 more
Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.
BiotechMedical DevicesLa Jolla, US
Zachary D. Hornby(Executive Officer, Director)inRobert Doebele(Chief Medical Officer)inChristian Hassig(Chief Scientific Officer)Jessica Oien(Chief Legal Officer and Corporate Secretary)in
BoardBenjamin Cravatt, Ph.D.(Director)
Board seatKristina Burow· per SEC Form D
Co-investorsNextech InvestRA CapitalAlexandriaCity Hill VenturesNEXTECH ONCOLOGY SCSPSectoral Asset Management+4 more
Enliven Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics using a precision medicine approach, with a focus on oncology and hematology.
BiotechHealthtechBoulder, US
Sam Kintz(Co-founder and Head of Pipeline)inJoe Lyssikatos(Co-founder and Research Fellow)Anish Patel(Co-founder and Chief Operating Officer)Rick Fair(Chief Executive Officer and Member of the Board of Directors)inHelen Collins(Chief Medical Officer)inBen Hohl(Chief Financial Officer and Head of Corporate Development)in
Board seatRichard Heyman· per SEC Form D · $90M raise · filed Apr 2024
Co-investors5AM VenturesOrbiMedPfizer Venture InvestmentsRoche Venture FundBay City CapitalJanus Henderson Investors+2 more
Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
BiotechDigital HealthMedical DevicesSan Diego, US
Faheem Hasnain(Executive Officer, Director)inChristian Waage(Executive Officer)inSheila Gujrathi, MD(Founder)inBryan Giraudo(Executive Officer)Laura Carter, Ph.D.(Executive Officer)Robert Smith(Executive Officer)
Board seatKristina BurowRobert Nelsen· per SEC Form D
Co-investorsBay City CapitalEcoR1 CapitalFoothill VenturesNew Enterprise Associates (NEA)Pivotal Life SciencesSamsara BioCapital+3 more
GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesMenlo Park, US
Jeffrey T. Huber(Director)Joshua Ofman, MD, MSHS(Chief Executive Officer)inAaron Freidin(Executive Officer)inJosh Ofman(Executive Officer)inRobert Ragusa(Executive Officer, Director)Jennifer Cook(Executive Officer, Director)in
Board seatRobert Nelsen· per SEC Form D
Co-investorsAmino CapitalBezos ExpeditionsBluebird VenturesDecheng CapitalDentsu VenturesFelicis Ventures+13 more
-2.png)
Neumora is a clinical research company developing investigational medications, with a focus on conducting clinical trials to obtain regulatory approval and make treatments available to patients.
BiotechDeep TechDigital HealthMedical DevicesWatertown, US
Paul L. Berns(Chairman and Chief Executive Officer)Joshua Pinto(Executive Officer)Tamara Tompkins(Executive Officer)inKari Stefansson(Director)Maykin Ho(Director)Alaa Halawa(Director)
Board seatRobert NelsenKristina Burow· per SEC Form D
Co-investorsCatalio Capital Management, LPF-Prime CapitalK2 HealthVenturesMercury FundPremier PartnersSoftBank Vision Fund+10 more
Quanterix develops technology for highly sensitive detection of protein biomarkers using non-invasive sample types, aimed at early disease detection and prevention.
BiotechDigital HealthHealthtechMedical DevicesLexington, US
David Walt(Director)inErnest Orticerio(Executive Officer)Ernest Oriticerio(Executive Officer)Masoud Toloue(Former Chief Executive Officer)in
BoardJohn Connolly(Director)in
Board seatKeith Crandell· per SEC Form D
Co-investorsBain Capital VenturesFoothill VenturesKhosla VenturesIn-Q-TelNovalis LifeSciences
Scholar Rock is a biopharmaceutical company that develops therapies targeting growth factor proteins to treat serious diseases.
BiotechCambridge, US
Nagesh Mahanthappa(Executive Officer, Director)inTimothy Springer(Director)David Hallal(Chief Executive Officer, Chairman and Director)inAkshay Vaishnaw(President of Research & Development and Director)inR. Keith Woods(Chief Operating Officer)inVikas Sinha(Chief Financial Officer)in
Board seatKristina Burow· per SEC Form D
Co-investorsAisling CapitalEcoR1 CapitalPolaris PartnersThe Kraft Group
Clinical-stage biopharmaceutical company focused on discovery and development of innovative medicines for serious diseases by targeting the Transforming Growth Factor Beta pathway.
BiotechCambridge, US
Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)Yung H. Chyung(Executive Officer)Elan Z. Ezickson(Executive Officer)Akshay Vaishnaw(President of Research & Development and Director)R. Keith Woods(Chief Operating Officer)in
Board seatKristina Burow· per SEC Form D · $47M raise · filed Jan 2018
Co-investorsSamsara BioCapitalEcoR1 CapitalPolaris Partners
Seaport Therapeutics develops therapeutics and medicines.
BiotechMental HealthBoston, US
Daphne Zohar(Founder, CEO & Board Member)inSteven Paul, M.D.(Founder, Board Chair)inMichael Chen, Ph.D.(Co-Founder, Chief Scientific Officer)Michael Chen(Executive Officer)inLana Gladstein(Executive Officer)inAntony Loebel(Executive Officer)in
Board seatRobert Nelsen· per SEC Form D
Co-investorsForesite CapitalHAWKTAILPureTech HealthSofinnova VenturesCPP InvestmentsGeneral Atlantic+3 more
Twist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals.
BiotechDeep TechSemiconductorsSouth San Francisco, US
William Charles Banyai(Executive Officer, Director, Promoter)Bill James Peck(Executive Officer, Promoter)Emily Leproust(Founder)inEmily M. Leproust(Chief Executive Officer and Chair of the Board)inEmily Leproust, PhD(CEO and Co-Founder of Twist)Patrick Finn(President and Chief Operating Officer)in
Board seatKeith Crandell· per SEC Form D
Co-investors+ND Capital3E Bioventures CapitalAsset Management CompanyATEL VenturesBay City CapitalBlack Opal Ventures+10 more
Vir Biotechnology develops treatments for infectious diseases and oncology, leveraging immunology-focused scientific capabilities.
AI & Machine LearningBiotechDigital HealthMedical DevicesSan Francisco, US
Marianne De Backer(CEO)inHerbert Virgin(Executive Officer)Howard Horn(Executive Officer)inAlex Bangs(Executive Officer)inMarianne De Backer, M.Sc., Ph.D., MBA(President, Chief Executive Officer and Director)
BoardGeorge Scangos(Executive Officer, Director)
Board seatRobert NelsenKristina BurowVicki Sato· per SEC Form D
Co-investorsAlta PartnersGV (Google Ventures)SoftBank Vision Fund8VCALTITUDE LIFE SCIENCE VENTURESSoftBank Group
Voyager Therapeutics is a biotechnology company developing genetic medicines for neurological diseases of the central nervous system, including Alzheimer's disease, ALS, and Parkinson's disease.
BiotechHealthtechLexington, US
Todd Carter(Executive Officer)inRobin Swartz(Executive Officer)inAlfred Sandrock(Executive Officer, Director)Peter Pfreundschuh(Executive Officer)inNathan Jorgensen(Chief Financial Officer; Principal Financial Officer and Principal Accounting Officer)Steven Hyman(Director)
Board seatGeorge Scangos· per SEC Form D · $20M raise · filed Jan 2024
Co-investorsFidelity InvestmentsThird Rock Ventures
Agios is a biopharmaceutical company developing therapies for rare diseases, with a primary focus on hemolytic anemias including pyruvate kinase deficiency, thalassemia, and sickle cell disease.
BiotechHealthtechMedical Devices
Lewis C. Cantley, Ph.D.(Founder)Tak Mak, Ph.D.(Founder)Craig B. Thompson, M.D.(Founder)Brian Goff(Chief Executive Officer)in
Co-investorsThird Rock VenturesFlagship VenturesSamsara BioCapital
Alnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.
BiotechDigital HealthMedical DevicesCambridge, US
John Maraganore(Founder)inPhillip Sharp(Founder)David Bartel(Founder)Thomas Tuschl(Founder)Paul Schimmel(Founder)Phillip Zamore(Founder)
Co-investorsAtlas VentureBlackstone Life SciencesCardinal PartnersInvivo Capital Partners
Denali Therapeutics develops therapeutics for neurodegenerative diseases.
BiotechHealthtechMedical DevicesSan Francisco, US
Marc Tessier-Lavigne(Director)inRyan Watts(Executive Officer, Director)inAlexander O. Schuth(Executive Officer)inRyan J. Watts(President, Chief Executive Officer and Director)inCarole Ho(Executive Officer)inSteve E. Krognes(Director)in
Co-investorsEcoR1 CapitalF-Prime CapitalForesite CapitalGV (Google Ventures)Flagship PioneeringFlagship Ventures
Erasca is a clinical-stage oncology company developing therapies targeting RAS- and MAPK pathway-driven cancers using a modality-agnostic approach including small molecules, large molecules, and protein degraders.
BiotechDeep TechDigital HealthMedical DevicesSan Diego, US
Jonathan E. Lim, M.D.(Chairman, CEO and Co-founder)Gary Yeung, CFA(Chief Business Officer)in
BoardAlexander W. Casdin(Director)Pratik S. Multani, M.D.(Director)Valerie Harding-Start(Director)James A. Bristol, Ph.D.(Director)
PartnerKristina Burow· quoted
Co-investorsAndreessen HorowitzColt VenturesEvolution VC PartnersFrazier Life SciencesLifeSci Venture PartnersCity Hill Ventures+1 more
Generate:Biomedicines develops protein-based therapeutics using artificial intelligence and machine learning in a field it calls Generative Biology, combining computational protein design with biological engineering.
AI & Machine LearningBiotechDeep TechSomerville, US
Gevorg Grigoryan(Co-Founder & Chief Technology Officer)inMichael Nally(Chief Executive Officer)in
Co-investorsFlagship PioneeringAlumni VenturesMarch Capital PartnersAlaska Permanent Fund CorporationALTITUDE LIFE SCIENCE VENTURESAmgen Ventures+2 more
Kardigan develops targeted cardiovascular treatments through a discovery and translational research platform, with a pipeline of late-stage drug candidates aimed at functional cures for cardiovascular disease.
AI & Machine LearningBiotechHealthtechMedical Devices
Co-investorsCatalio Capital Management, LPSequoia CapitalSequoia HeritageT. Rowe PriceVenrock
Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.
BiotechDigital HealthMedical DevicesLa Jolla, US
TROY WILSON(Executive Officer, Director)inPINGDA REN(Executive Officer)inYI LIU(Executive Officer)inTroy Wilson(Founder)inTroy E. Wilson(President and Chief Executive Officer, Chairman of the Board)inTroy Wilson, Ph.D., J.D.(Co-founder; President, Chief Executive Officer and Chairman of the Board)
Co-investorsAvoro Capital AdvisorsEcoR1 CapitalForesite CapitalNextech InvestOUP (Osage University Partners)
Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.
AI & Machine LearningBiotechSouth San Francisco, US
Charles Homcy(Director)Jason Coloma(Chief Executive Officer)in
Co-investorsAndreessen HorowitzForesite CapitalFrazier Life SciencesGV (Google Ventures)Hercules Capital, Inc.Alexandria+9 more
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)in
Co-investorsCatalio Capital Management, LPForesite CapitalFrazier Life SciencesGeneral CatalystGV (Google Ventures)HBM Healthcare Investments+9 more
.png)
PerkinElmer is a scientific instrument and technology company that provides analytical tools and services for research, diagnostics, and life sciences applications.
BiotechDeep TechEnterprise SoftwareHealthtechMedical DevicesWaltham, US
Richard Scott PerkinJames M. Mock(Executive Officer)Andrew Okun(Executive Officer)inJoel S. Goldberg(Executive Officer)Prahlad Singh(Executive Officer, Director)inTajinder Vohra(Executive Officer)in
Co-investorsAmpersandPartners for GrowthPartners for Growth (PFG)
Pulmatrix develops inhaled dry-powder therapies using its proprietary iSPERSE technology, which uses small, dense, dispersible particles to deliver respiratory and non-respiratory drugs via the respiratory system.
BiotechDeep TechHealthtechMedical DevicesFramingham, US
Anand Varadan(Director)inRichard Batycky(Director)Peter Ludlum(Interim Chief Executive Officer)Hojabr Alimi(Executive Officer)Sameer Harish(Executive Officer)
BoardRichard Conley(Director)
Co-investors5AM VenturesALTITUDE LIFE SCIENCE VENTURESPolaris Partners
Rapport is a biopharmaceutical company developing novel therapeutics.
BiotechHealthtechMedical Devices
Abe Ceesay(President)Cheryl GaultinDr. SevignyAbraham N. Ceesay(President and Chief Executive Officer and Director)
Co-investorsSofinnova VenturesCapital GroupJohnson & Johnson Innovation – JJDCThird Rock Ventures
Basking Biosciences develops therapeutics for thrombosis, vascular biology, and ischemic disease.
BiotechDigital HealthHealthtechMedical DevicesCary, US
Shahid Nimjee(Co-founder, Chief Scientific Officer and Stroke Clinical Lead)inBruce Sullenger(Co-founder)Julia Owens(Executive Officer, Director, Promoter)inRichard Shea(Executive Officer, Director, Promoter)in
BoardHannah Chang(Director)Aiden Aceves(Director)in
Board seatSteve Gillis· per SEC Form D
Co-investorsInsight PartnersBroadview VenturesMedblueSolas BioVenturesPlatanus VenturesRev1 Ventures+1 more
Cytrellis develops medical device technologies focused on aesthetic and reconstructive treatments, with expertise spanning dermatology, plastic surgery, and wound healing applications.
BiotechHealthtechMedical DevicesWoburn, US
Rox Anderson, MD(Founder, Medical / Technology Advisor)William G. Austen, Jr. MD(Founder, Medical / Technology Advisor)Doug Levinson, PhD(Founder)Denise Dajles, PhD(President & CEO)John McDonough(Executive Officer, Director)inDavid Stone(Executive Officer)in
Board seatKeith Crandell· per SEC Form D
Co-investorsSands Capital Ventures
IngredientWerks is a molecular farming company that engineers plants to produce plant-based proteins and ingredients for the alternative protein market.
AgTechBiotechFoodTechWoburn, US
Matt Plavan(Chief Executive Officer)inMichael Raab(R&D Lead)Jeremy Schley-Johnson(Vice President)inSteve Snyder(Director)James Schultz(Director)
Board seatClinton Bybee· per SEC Form D
Co-investorsOpen PrairieCultivian Sandbox VenturesSandbox Industries
Vizgen develops high-throughput spatial profiling technologies, including MERFISH-based spatial genomics and spatial proteomics tools for life science research and precision oncology.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesCambridge, US
George Emanuel(Scientific Cofounder, VP & Portfolio Owner, Instruments)inJiang He(Scientific Cofounder, VP & Portfolio Owner, Reagents & Scientific Affairs)inXiaowei Zhuang(Founder; Professor, Harvard University)inFenel Eloi(Director)Rob Carson(Chief Executive Officer)inSimona Levi(Chief Legal Officer)in
Board seatKeith Crandell· per SEC Form D
Co-investorsNorthpond Ventures6 Dimensions CapitalAlly Bridge GroupApplied VenturesKilonova CapitalPura Vida Investments+3 more
Vizgen develops spatial profiling instruments and reagents for high-throughput analysis of gene expression and protein distribution in tissue samples.
AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, US
George Emanuel(Scientific Cofounder, VP & Portfolio Owner, Instruments)inJiang He(Scientific Cofounder, VP & Portfolio Owner, Reagents & Scientific Affairs)inRobert Carson(Executive Officer, Director)Terry Lo(Director)inSeth Benson(Executive Officer)inSimona Levi(Executive Officer)in
Board seatKeith Crandell· per SEC Form D
Co-investorsM VenturesNorthpond VenturesIllumina VenturesNovalis LifeSciences
Aera Therapeutics develops genetic medicines using next-generation delivery technologies and precision payloads optimized for specific diseases.
AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, US
Feng Zhang, Ph.D.(Scientific Founder & Board Observer)Akin Akinc, Ph.D.(Chief Executive Officer & Board Director)
Co-investorsLux CapitalF-Prime CapitalGV (Google Ventures)JDRF T1D FundNewpath Partners
Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.
BiotechDeep TechDigital HealthMedical DevicesSan Diego, US
Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)inANDRÉS BRATT-LEAL, Ph.D.(Co-Founder; Senior Vice President, Research & Development)Damien McDevitt(President and Chief Executive Officer)inDAMIEN MCDEVITT, Ph.D.(President and Chief Executive Officer)
Co-investorsLifeforce CapitalOrbiMedDomain AssociatesEDB InvestmentsSection 32Frazier Life Sciences+8 more
Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.
AI & Machine LearningBiotechDeep TechBoston, US
Richard Young, Ph.D.(Director)inAnthony Hyman, Ph.D.(Director)Tony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)inAmeet Nathwani, M.D.(Executive Officer, Director)in
Co-investorsEcoR1 CapitalGeneral CatalystSamsara BioCapital6 Dimensions CapitalInnovation EndeavorsLeaps by Bayer+6 more
Lifordi Immunotherapeutics develops treatments for immunology and rare diseases through discovery, clinical development, and commercialization.
BiotechDeep TechHealthtechBurlington, MA, US
Jay Rothstein, Ph.D.(Scientific Co-Founder and Advisor)Arthur O. Tzianabos, Ph.D.(President and CEO)Naina Bhasin, Ph.D.(Chief Business Officer)Arthur Tzianabos, Ph.D.(President & Chief Executive Officer)
Co-investorsAtlas VentureSanofi Ventures5AM Ventures
Magnet Biomedicine develops TrueGlue™, a molecular glue discovery platform for designing small molecule therapeutics that induce novel protein-protein interactions to treat cancer and immune disorders.
AI & Machine LearningBiotechMedical DevicesBoston, US
Benjamin F. Cravatt, PhD(Founder & Advisor)David A. Spiegel, MD, PhD(Founder & Advisor)Michael Rosbash, PhD(Founder & Advisor)Richa Saxena, PhD(Founder & Advisor)Stuart Schreiber, PhD(Founder & Advisor)Brian Safina(President & Chief Executive Officer)in
Co-investorsNewpath PartnersTaiho Ventures, LLC
Moleculent develops biological discovery and disease understanding tools for scientists.
AI & Machine LearningBiotechDeep TechSolna, SE
Fredrik Roos(CTO & Co-founder)in
Co-investorsEIR Ventures
Paradigm Health provides technology and services that integrate with healthcare provider organizations to improve the clinical trial process.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesSaaSColumbus, US
Kent Thoelke(Founder & CEO)inJonathan Hirsch(Chief Strategy and Growth Officer)Jay Trepanier(Chief Financial Officer)inElijah Meerson(Chief Technology Officer)inMichelle Lee(Chief Operating Officer)in
Co-investorsGeneral CatalystGV (Google Ventures)Lux CapitalF-Prime CapitalJobsOhio VenturesMagnetic Ventures+1 more
Pelage develops regenerative medicines for hair loss based on stem cell biology, with a lead candidate (PP405) that is a topical small-molecule drug designed to reactivate dormant hair follicle stem cells.
BiotechHealthtechLongevityLos Angeles, US
William Edward Lowry(Director)inHeather Christofk(Executive Officer)William Lowry(PhD)inChristina Weng(Chief Medical Officer)inNathan Wheeler(Chief Operating Officer)in
BoardCathy Friedman(Director)in
Co-investorsGV (Google Ventures)HAWKTAILVisionary VenturesYK Bioventures
Pretzel Therapeutics develops therapeutics targeting bioenergetic dysfunction and mitochondrial disease by addressing defects in mitochondrial DNA function and gene expression.
BiotechDeep TechHealthtechMedical Devices
Michal Minczuk(Co-Founder)inGabriel Martinez(Chief Scientific Officer & Co-Founder)Claes Gustafsson(Co-Founder)Maria Falkenberg(Co-Founder)Nils-Göran Larsson(Co-Founder)Gabriel Martinez, Ph.D.(Chief Scientific Officer & Co-Founder)
Co-investorsCambridge Innovation CapitalEIR VenturesAngelini VenturesGV (Google Ventures)HealthCapInvus+1 more
RhyGaze develops gene therapies using optogenetic proteins to restore sight in patients with vision loss caused by retinal photoreceptor dysfunction.
BiotechDigital HealthMedical DevicesBasel, CH
Botond Roska(Researcher (M.D., Ph.D.))Bence György(IOB Assistant Professor & Head of Clinical Translation)inKatherine High(CEO)in
Co-investorsNovartis Venture FundBioGeneration VenturesF-Prime CapitalGV (Google Ventures)
Tenvie is a clinical-stage biopharmaceutical company developing small molecule and biologic therapeutics for neurological and peripheral diseases.
BiotechMedical Devices
Tony Estrada(President & Chief Executive Officer)in
Co-investorsF-Prime CapitalBain Capital Life SciencesDigitalis VenturesForbionMubadala Capital
AIRNA develops genetic medicines that use ADAR, a naturally occurring human protein, to precisely edit RNA and treat genetic diseases without permanently modifying DNA.
AI & Machine LearningBiotechDeep TechHealthtechStanford, US
Thorsten Stafforst(Chairman of the Board of Directors)inKris ElveruminTodd Bazemore(Chief Executive Officer)inJin (Billy) Li(Treasurer and Secretary)inPaul Vogel(Chief Executive Officer and President)in
BoardRodger Novak(Chair)in
Co-investors+ND CapitalForbionVenrockFast Track InitiativeNextech InvestNovalis LifeSciences+2 more
Fabless US semiconductor company making ultralow-power non-volatile memory, ASICs and IoT embedded systems; acquired by Dialog in 2020.
Sunnyvale, US
Narbeh Derhacobian(Executive Officer, Director)inRon Shelton(Executive Officer)in
BoardMatt Boyle(Director)Alexei Andreev(Director)inBarry Cox(Director)
Board seatKeith Crandell· per SEC Form D · $12.5M raise · filed Sep 2015
US agricultural biotech that discovered microbe-based crop protection products; its assets were sold to Certis Biologicals and Ginkgo Bioworks in 2024.
AgTechResearch Triangle Park, US
Scott Uknes(Manager)inEric Ward(Manager)Paul Schulze-Lefert(President)Michael Koziel(Vice President and Manager)
BoardThomas Dietz(Manager)
Board seatKristina Burow· per SEC Form D
Co-investorsAliment CapitalBlue Horizon CorporationPontifax AgTechBill & Melinda Gates FoundationLeaps by BayerNovalis LifeSciences+1 more
Agrivida develops enzyme technology for animal feed and nutrition, improving efficiency in poultry, swine, and other livestock production.
AgTechBiotechFoodTechMassachusetts, US
R. Michael Raab(Executive Officer)Daniel Meagher(Executive Officer, Director)Jeremy Schley Johnson(Executive Officer)
BoardRob Johnson(Director)Mark Austin(Director)Robert Bucklin(Director)
Board seatClinton Bybee· per SEC Form D
Co-investorsMiddleland CapitalPresidio VenturesCultivian Sandbox VenturesDag VenturesKleiner Perkins
Alzheon is a clinical-stage biopharmaceutical company developing oral small-molecule drugs for Alzheimer's disease and other neurodegenerative disorders, with a Phase 3 program for its lead compound valiltramiprosate (ALZ-801).
BiotechDeep TechHealthtechFramingham, US
Martin Tolar, M.D., Ph.D.(President and Chief Executive Officer)Martin Tolar(Executive Officer, Director)inMartin Tolar, MD, PhD(Founder)inGlenn E. Pauly(Chief Commercial Officer)inSusan Abushakra, M.D.(Chief Medical Officer)inJohn Hey, Ph.D.(Chief Scientific Officer)
Board seatScott Minick· per SEC Form D · filed Feb 2015
Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches.
BiotechDigital HealthMedical DevicesCambridge, US
DAVID ARTHUR SCOTT(Executive Officer)inWINSTON XIA YAN(Executive Officer)FENG ZHANG(Director)Feng Zhang, Ph.D.(Arbor Co-founder and Scientific Advisory Board Chair)David Walt, Ph.D.(Arbor Co-founder)David Scott, Ph.D.(Arbor Co-founder)
Board seatKeith Crandell· per SEC Form D
Co-investorsIllumina VenturesOno Venture Investment, Inc.TCG CrossoverAlly Bridge GroupJanus Henderson InvestorsRevelation Partners+4 more
Areteia Therapeutics was a clinical-stage biotechnology company that is no longer operating.
BiotechChapel Hill, US
Robin Walker(Executive Officer)inChristopher Courts(Executive Officer)inJorge Bartolome(Executive Officer, Director)in
BoardBenjamin Gomez(Director)Adam Koppel(Director)inMichael E. Bozik(Director)
Board seatPaul Berns· per SEC Form D
Co-investorsBain Capital Life SciencesGV (Google Ventures)Solas BioVenturesAccess BiotechnologyMaverick CapitalSanofi Ventures+2 more
Seattle 'scientific wellness' startup that paired genetic, blood and microbiome testing with health coaching; closed in 2019.
HealthtechSeattle, US
Nathan Price(Director)Clayton Lewis(Executive Officer, Director)
BoardTim Kilgallon(Director)
Board seatRobert Nelsen· per SEC Form D · $30M raise · filed Jun 2017
Co-investorsCorewell Health VenturesPolaris Partners
Autobahn Therapeutics develops orally administered small molecule prodrugs using a brain-targeting chemistry platform to create regenerative medicines for central nervous system (CNS) disorders.
BiotechDeep TechMedical DevicesSan Diego, US
Kevin Finney(Chairman, President and CEO)inJohn Borkholder(Executive Officer)in
BoardThomas Cahill(Director)Timothy Anderson(Director)Philip J DeSouza(Director)
Board seatKristina Burow· per SEC Form D
Co-investorsCanaan PartnersMonograph Capital PartnersPfizer Venture InvestmentsSamsara BioCapitalNewpath Partners
Cooledge designs and manufactures specialized lighting solutions including LED luminaires, tunable white products, and architectural lighting systems for commercial and industrial applications.
Advanced ManufacturingCleantechConstruction TechHardwareRichmond, US
BillCalvin Wade Sheen(Executive Officer, Director)
BoardWilliam Sims(Director)Kirk A. Washington(Director)Geoff Catherwood(Director)inThomas Bilbrough(Director)
Board seatClinton Bybee· per SEC Form D
Co-investorsSaints CapitalYaletown PartnersBDC Venture Capital
Biotechnology company using multiplex gene editing to develop genetically engineered porcine organs for human transplantation.
BiotechBrookline, US
Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)
BoardGeorge M. Church(Director)
Board seatSteven Gillis· per SEC Form D
Co-investorsAlta PartnersCatalio Capital Management, LPHBM Healthcare InvestmentsHBM PartnersKhosla VenturesLifeSci Venture Partners+13 more
Elephas develops elive, a live-tissue platform technology that predicts immunotherapy response in cancer patients by measuring real-time immune activity in intact tumor tissue.
BiotechDigital HealthHealthtechMedical DevicesMadison, US
Jonathan Oliner(Executive Officer)inManeesh Arora(Founder)inMichelle B. Arora(Director)Terrence P. Brady(Executive Officer)
Board seatPaul Berns· per SEC Form D
Co-investorsNorthpond VenturesSands Capital Ventures
Seattle biotech that developed FDY-5301 for cardiac and skeletal muscle injury; ceased operations in February 2026.
BiotechSeattle, US
Mark Roth(Executive Officer, Director, Promoter)Brian Blackman(Executive Officer)Simon Tulloch(Executive Officer)Stephen Hill(Executive Officer, Director)
BoardPaulina Hill(Director)in
Board seatSteven Gillis· per SEC Form D
Co-investorsOUP (Osage University Partners)Polaris Partners
insitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines.
AI & Machine LearningBiotechSouth San Francisco, US
Daphne Koller(Founder & CEO)inDuane Valz(General Counsel)inMary Rozenman(Chief Financial Officer)in
BoardVijay Pande(Director)in
Board seatRobert Nelsen· per SEC Form D
Co-investorsAndreessen HorowitzDeviation CapitalForesite CapitalGV (Google Ventures)HOF CapitalSoftBank Vision Fund+9 more
Seattle-based cancer immunotherapy company developing CAR-T and TCR cell therapies; acquired by Celgene, now part of Bristol-Myers Squibb.
BiotechSeattle, US
Hans Bishop(Executive Officer, Director, Promoter)Richard Klausner(Director, Promoter)Bernard J. Cassidy(Executive Officer)Robert Azelby(Executive Officer)Sunil Agarwal(Executive Officer)Rupert Vessey(Director)
Board seatRobert Nelsen· per SEC Form D
Co-investorsBezos ExpeditionsRidgeback CapitalAlaska Permanent Fund CorporationCrestline InvestorsVenrock
San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.
BiotechSan Diego, US
Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)
BoardAmir Nashat(Director)in
Board seatKristina BurowRichard Heyman· per SEC Form D
Co-investorsage1EcoR1 CapitalLAVLifeSci Venture PartnersLilly Asia VenturesNew Enterprise Associates (NEA)+8 more
Metsera was a clinical-stage biotechnology company developing injectable and oral medicines for obesity and metabolic diseases, including next-generation GLP-1 and amylin-based therapies.
BiotechHealthtechMedical DevicesNew York, US
Clive A. Meanwell(Director)Christopher J. Visioli(Executive Officer)inBrian Hubbard(Executive Officer)inChristopher Whitten Bernard(Executive Officer, Director)Steven Marso(Executive Officer)
Board seatKristina BurowPaul Berns· per SEC Form D
Co-investorsAlpha Wave GlobalF-Prime CapitalGV (Google Ventures)RA CapitalSoftBank Vision FundJanus Henderson Investors+4 more
Mirador discovers and develops precision medicines for immune-mediated and immuno-fibrotic diseases using a target-patient matching approach.
AI & Machine LearningHealthtechMedical DevicesSan Diego, US
Mark C. McKenna(Executive Officer, Director)inJoseph Papa(Director)Scott Glenn(Director)Vika Brough(Executive Officer)Timothy K. Andrews(Executive Officer)
Board seatKristina BurowPaul Berns· per SEC Form D
Co-investorsAquiline Technology GrowthOrbiMedSanofi VenturesInvusPoint72Venrock Healthcare Capital Partners
Nanosys develops Quantum Dot technology and materials, providing samples, R&D collaboration, and scaled production for partners building display and other advanced-material products.
Advanced ManufacturingDeep TechHardwareNew MaterialsSemiconductorsMilpitas, US
Jason Hartlove(Executive Officer, Director)inJian Chen(Executive Officer)inRussell Kempt(Executive Officer)inNoland Granberry(Executive Officer)inDr. Martin Devenney(Co Chief Executive Officer and Assistant Secretary)Dr. Hirokazu Sasaki(President & CEO and Treasurer, Shoei Electronic Materials, Inc. • Operating Officer & Division Manager QD Business Dept., Shoei Chemical, Inc.)
Board seatKeith Crandell· per SEC Form D · $10M raise · filed Mar 2015
Co-investorsArcher Capital GroupArcher Venture CapitalProspect Venture PartnersStructural CapitalTEL Venture Capital, Inc.Venrock+3 more
RNA therapeutics company with a chip-based mRNA manufacturing platform; acquired by Medici Therapeutics in November 2025.
BiotechEmeryville, US
Igor Khandros(Executive Officer, Director)
Board seatRobert Nelsen· per SEC Form D
Co-investors+ND CapitalBluebird VenturesCraft VenturesFounders FundParadigmSam Altman+1 more
Clinical-stage immuno-oncology company developing antibodies derived from the immune systems of 'Elite' cancer responders.
BiotechHouston, US
Alice Bexon(Executive Officer)inClifford J. Stocks(Director, Executive Officer)inKamal D. Puri(Executive Officer)inChris Russell(Executive Officer)inRuss Hawkinson(Executive Officer)
Board seatSteven Gillis· per SEC Form D
Co-investors3B Future Health FundCanaan PartnersGreatPoint VenturesRiverVest Venture PartnersAlexandriaBering Capital+5 more
Pheast Therapeutics develops immunotherapies targeting cancer, building on foundational research from Stanford's stem cell research institute.
BiotechHealthtechMedical DevicesRedwood City, US
Irv Weissman(Cofounder, Scientific Advisor, Board Director)Ravi Majeti(Cofounder, Scientific Advisor, Board Observer)Amira Barkal(Principal Founder, Scientific Advisor, Board Director)inRoy Maute(Cofounder & Chief Executive Officer)in
BoardJacob Vogelstein(Director)
Board seatSteven Gillis· per SEC Form D
Co-investorsCatalio Capital Management, LPAlexandriaCatalio Capital Management
Proniras Corporation is a clinical-stage biotechnology company developing novel small-molecule therapeutics for substance use disorders and specialty central nervous system (CNS) conditions, including treatments for opioid withdrawal and seizure disorders.
BiotechHealthtechSeattle, US
CHRISTOPHER TOOMBS(Executive Officer)inLINDSAY RAYLE(Executive Officer, Promoter)M. Johnston Erwin(Director)David Schubert(Executive Officer, Promoter)
BoardThong Le(Executive Officer, Director, Promoter)
Board seatSteven Gillis· per SEC Form D
Co-investorsACCELERATOR LIFE SCIENCE PARTNERSAlexandriaWRF Capital
Ramona Optics builds parallelized multi-camera array microscope systems for imaging and analyzing small model organisms and cell cultures in multi-well plates.
BiotechDeep TechHardwareDurham, US
Roarke Horstmeyer(Director)inMark Harfouche(Executive Officer, Director)inRobert Horstmeyer(Director)Margaret Aery(Executive Officer)inGregor Horstmeyer(Executive Officer, Director)
Board seatSean KendallPatrick Weiss· per SEC Form D · $31M raise · filed Mar 2026
Co-investorsThe E14 Fund
Resilience is a contract development and manufacturing organization (CDMO) that manufactures complex pharmaceutical products and active pharmaceutical ingredients to broaden access to medicines and protect biopharmaceutical supply chains against disruption.
Advanced ManufacturingBiotechEnterprise SoftwareBlue Ash, US
William S. Marth(Chief Executive Officer)William S. Marth, RPh., MBA(President & CEO)
Board seatRobert Nelsen· per SEC Form D
Co-investors8VCCatalio Capital Management, LPGlobal Health Investment CorporationGV (Google Ventures)Koch Disruptive TechnologiesLux Capital+13 more
Rezo maps disease networks to find insights into disease biology for drug discovery.
AI & Machine LearningBiotechDeep TechSan Francisco, US
Nevan Krogan(Co-Founder)inSourav Bandyopadhyay(Co-Founder)inNorbert Bischofberger(Co-Founder)Natalia Jura(Co-Founder)George Scangos(Co-Founder)Kevan Shokat(Co-Founder)
Board seatGeorge Scangos· per SEC Form D · $80.1M raise · filed Aug 2025
Co-investorsAndreessen HorowitzNorwest Venture PartnersHAWKTAILSR One Capital ManagementValkyrie Ventures Management, LlcSV Angel
Rippl delivers evidence-based dementia care through a combination of technology and human support for people living with dementia and their families.
Digital HealthHealthtechSeattle, US
Kris Engskov(Co-founder & CEO)inRobert Nelsen(Co-Founder & Board Chair)Paul Engskov(Executive Officer, Director)
BoardHolly Maloney(Director)inIyah Romm(Director)Ryan Watts(Director)
Board seatRobert Nelsen· per SEC Form D
Co-investors1843 CapitalCity LightEquitage Ventures, L.L.C.F-Prime CapitalGeneral CatalystGV (Google Ventures)+2 more
Sana is a biotech company developing engineered cell medicines, including gene therapies for gene modification and delivery, cell replacement therapies using stem cell biology, and manufacturing solutions to improve patient access to these treatments.
BiotechHealthtechMedical DevicesSeattle, US
Richard Mulligan(Director)inHans Bishop(Director)Steve Harr(President and Chief Executive Officer)James J. MacDonald(Executive Officer)Nathan Hardy(Executive Officer)
.jpg?itok=YnNGtnt9)
BoardGeoffrey von Maltzahn(Director)in
Board seatRobert Nelsen· per SEC Form D
Co-investorsAmerican Family VenturesF-Prime CapitalFlagship PioneeringGV (Google Ventures)Innovating CapitalJDRF T1D Fund+7 more
Semprius was a Durham, NC developer of micro-transfer-printed high-concentration photovoltaic solar modules, spun out of the University of Illinois.
Durham, US
JOHN ROGERS(Executive Officer, Director)JOSEPH CARR(Executive Officer, Director)HELENA YEE(Executive Officer)JACK BARRY(Executive Officer)
BoardGREG WOLF(Director)
Board seatClinton Bybee· per SEC Form D
Co-investorsApplied VenturesHG VenturesIllinois VenturesIn-Q-Tel
Seranova is a biotech company that combines REAP autoantibody profiling with clinically linked patient cohorts to identify naturally occurring protective autoantibodies against specific extracellular targets and translate those protective associations into therapeutic hypotheses.
AI & Machine LearningBiotechDeep TechNew Haven, US
Aaron Ring(Manager)inBeatrice McQueen(Executive Officer)
BoardJim Tananbaum(Manager)
Board seatSabah Oney· per SEC Form D · $10M raise · filed Feb 2024
Co-investorsAxial VCForesite Capital
Westlake Village dermatology company developing late-stage topical and photoparticle skin treatments; assets sold to Sebacia in 2020.
BiotechWeslake Village, US
Frederick C. Beddingfield III(Executive Officer, Director)Todd Harris(Director, Executive Officer)inDiane Stroehmann(Executive Officer)inPaul F. Lizzul(Executive Officer)inRic Peterson(Executive Officer)inTimothy K. Andrews(Executive Officer)
Board seatRobert NelsenKristina Burow· per SEC Form D · $40.5M raise · filed May 2017
San Francisco catalyst company that converted natural gas to ethylene and fuels; acquired by McDermott in 2019.
San Francisco, US
Edward J Dineen(Executive Officer, Director)Jeffrey P. Wood(Executive Officer)
BoardMichel Maloof(Director)Leighton Read(Director)Paula Reynolds(Director)
Board seatClinton Bybee· per SEC Form D · $25.7M raise · filed Jan 2016
Co-investorsLux CapitalPresidio VenturesKleiner PerkinsSaudi Aramco Energy Ventures
Boston-area biotech developing gene therapies for genetic causes of pediatric hearing loss.
BiotechCambridge, US
Giampiero De Luca(Director)Jodi A. Cook(Executive Officer, Director)Will McLean(Executive Officer)
Board seatSteve Gillis· per SEC Form D
Co-investorsArkin Capital
Slingshot Biosciences makes synthetic cell mimics used as standardized reference controls for flow cytometry and cell-based assays.
Emeryville, US
Jeff Kim(Founder)inAdam Wieschhaus(Director)Ronald J. Silberman(Director)
Board seatCorey RitterPatrick Weiss· per SEC Form D
Co-investorsAnterra CapitalNorthpond Ventures
SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way.
BiotechDeep TechDigital HealthHealthtechSouth San Francisco, US
Kenneth Greenberg(Co-Founder, President & CEO)in
Board seatSteven Gillis· per SEC Form D
Co-investorsVida VenturesLeaps by BayerFoothill VenturesIllumina VenturesMedical Excellence CapitalVivo Capital+8 more
Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.
Cambridge, US
Nancy Simonian(CEO)
Board seatRobert NelsenVicki Sato· per SEC Form D
Co-investorsAisling CapitalQuan CapitalAlexandriaAlly Bridge GroupBain CapitalBain Capital Life Sciences+11 more
Treeline develops therapeutics focused on oncology, leveraging insights from clinical practice and laboratory research.
AI & Machine LearningBiotechHealthtechMedical DevicesWatertown, US
Joshua H. Bilenker(Executive Officer, Director, Promoter)Jeffrey Engelman(Executive Officer, Director, Promoter)inJosh Bilenker(Founder)in
BoardAli Satvat(Director)David Schenkein(Director)in
Board seatKristina Burow· per SEC Form D
Co-investorsAisling CapitalGV (Google Ventures)OrbiMedCasdin CapitalFidelity InvestmentsRock Springs Capital+1 more
Unity Biotechnology was a biotechnology company that is no longer operating.
BiotechBrisbane, US
Nathaniel E. David(Executive Officer, Director)inDan Marquess(Executive Officer)inKeith Leonard(Executive Officer, Director)inTamara Tompkins(Executive Officer)inBob Goeltz(Executive Officer)inJamie Dananberg(Executive Officer)in
Board seatRobert NelsenKristina Burow· per SEC Form D
Co-investorsage1Alumni VenturesCycad Group LLCEcoR1 CapitalKhosla VenturesVenrock+6 more
Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins.
AI & Machine LearningBiotechDeep TechPrinceton, US
Ben Cravatt(Scientific Founder)Phil Baran(Scientific Founder)Jin-Quan Yu(Scientific Founder)Aleksandra Rizo(President and Chief Executive Officer)in
BoardJohn Park(Executive Officer)John Clarke(Executive Officer, Director)in
Board seatKristina BurowRichard Heyman· per SEC Form D
Co-investorsAvoro Capital AdvisorsCardinal PartnersNextech InvestSoftBank Vision FundAlexandriaALTITUDE LIFE SCIENCE VENTURES+4 more
Company producing world's first multi-material 3D printer capable of printing functional features with variable material properties.
Somerville, US
Jennifer A. Lewis(Executive Officer, Director)
BoardJiong Ma(Director)
Board seatClinton Bybee· per SEC Form D
Co-investorsBraemar Energy VenturesOUP (Osage University Partners)In-Q-Tel
Subsea and terrestrial optical transport supplier whose assets, rescued by H.I.G. in 2017, are being bought by Prysmian and Fincantieri.
Allen, US
Keith Henderson(Executive Officer)inLes Barkley(Executive Officer)inPaul Colan(Executive Officer)inJon Hopper(Executive Officer, Director)inGary Otake(Executive Officer)inHerve Fevrier(Executive Officer)
Board seatClinton Bybee· per SEC Form D
Co-investorsAristos VenturesNew Enterprise Associates (NEA)Wellcome Trust
Xtremity makes the XtremityTT, a thermoformable definitive prosthetic socket system built from an injection-molded, carbon-reinforced polymer preform that clinicians can heat, form, and assemble in about an hour and re-adjust via spot-heating.
HardwareHealthtechMedical DevicesNew MaterialsAspen, US
Mark Joseph(Inventor/Product Designer, company founder)Miguelangel Sosa(Executive Officer, Director)Amy Hill(Executive Officer)Scott Ward(Executive Officer)Maynard Carkhuff(President & CEO)
Board seatRobert Nelsen· per SEC Form D · $15M raise · filed Jun 2021
Co-investorsDecheng CapitalRsquared
Accompany was a relationship intelligence and business insights platform that has been acquired by Cisco and integrated into their collaboration products suite.
Enterprise SoftwareSaaS
Ryan McDonough(Founder)in
Co-investorsCRV (Charles River Ventures)Vista Venture PartnersICONIQ CapitalIVP (Institutional Venture Partners)Venrock
Bethesda-based provider of in-home and virtual primary, behavioral and social care for low-income patients with complex needs.
HealthtechBethesda, US
Rahul Rajkumar(Executive Officer, Director)in
BoardBryan Roberts(Director)Robert Kocher(Director)Stephanie Lovell(Director)Vivian Riefberg(Director)
Co-investorsIVP (Institutional Venture Partners)VenrockVenrock Associates
Ahura Scientific offers portable analytical instruments (under the Thermo Scientific brand) that use XRF, NIR, Raman, and FTIR technologies for rapid chemical identification and material verification in field environments.
Advanced ManufacturingDeep TechHardware
Co-investorsCastile VenturesFuse Capital
Akamis Bio develops oncolytic immunotherapies for colorectal cancer treatment, aiming to offer alternatives to surgery that preserve patient function and quality of life.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsSR One Capital ManagementWestlake Village BioPartners
Aledade is an accountable care organization (ACO) partner that works with primary care organizations to improve patient outcomes and healthcare quality.
Enterprise SoftwareHealthtechBethesda, US
Bijan Salehizadeh(Co-founder)inFarzad Mostashari(Chief Executive Officer and Co-Founder)inMat Kendall(President and Co-Founder)in
BoardRobert Kocher(Director)in
Co-investorsActivate Venture PartnersEcho Health VenturesGV (Google Ventures)Intrepid Growth PartnersIVP (Institutional Venture Partners)Lightspeed Venture Partners+12 more
Altos Labs develops computational and scientific approaches to reverse disease through breakthrough medicines, operating research institutes focused on cell health, computation, and drug discovery.
BiotechDeep TechLongevityBay Area, US
Richard Murray(CEO and Founder)Shinya Yamanaka(Chief Scientific Advisor and Founder)Hal Barron(CEO and Founder)inRichard Klausner(Founder)Hans Bishop(President and Founder)Juan Carlos Izpisua Belmonte(Founding Scientist and Senior Vice President)in
Co-investors8VCGeneral CatalystLuma Group
Boulder-based biopharmaceutical company developing targeted small molecule cancer drugs; acquired by Pfizer in 2019.
Co-investorsFrazier Life SciencesRidgeback CapitalBoulder Ventures
Arsenal Biosciences is a clinical-stage company developing programmable cell therapies to treat solid tumors.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Ken Drazan(Founder)James Ahlers(Executive Officer)Irene Pleasure(Executive Officer)Margaret Nibbi(Executive Officer)
BoardValentin Barsan(Director)Sean Parker(Director)
Co-investorsHitachi VenturesKleiner PerkinsLuma GroupOUP (Osage University Partners)SoftBank Vision FundWestlake Village BioPartners+2 more
Co-investorsAlta PartnersDC Investment PartnersLongwood FundNextech InvestPathway to CuresAtlas Venture+6 more
bit.bio is a synthetic biology company that engineers human induced pluripotent stem cells into defined cell types for research, drug discovery, and cell therapy applications.
BiotechDeep TechHealthtechMedical Devices
Dr Mark Kotter(Founder)Przemek Obloj(CEO)inEmma Pepperellin
Co-investorsForesite CapitalBlueYard CapitalDynamk CapitalGood AI CapitalHarmonix FundHAWKTAIL+5 more
Genetix Biotherapeutics (formerly bluebird bio) develops gene therapies for patients with rare genetic diseases including sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy.
BiotechLongevityMedical DevicesCambridge, US
David Meek(Chief Executive Officer)inBrian Riley(President & Chief Technical Officer)inJoanne Lager(Chief Medical Officer)inWendy DiCicco(Chief Financial Officer)inAdrian Chaisson(Chief of Staff)inJason Cole(Executive Officer)
Co-investorsEaston CapitalRA CapitalSanofi VenturesThink+ Ventures Management, LlcWakestream Ventures
Hong Kong-listed (2137.HK) biotech founded in 2018 developing infectious disease therapies, led by hepatitis B functional-cure programs.
Co-investors6 Dimensions CapitalBlue Pool CapitalBoyu CapitalSequoia Capital
Carrick Therapeutics is a biopharmaceutical company with a leadership team experienced in oncology drug development and commercialization.
BiotechDigital HealthHealthtechMedical DevicesBoston, US
Timothy Pearson(CEO)Ash Bahl(CSO)inJenny Horsfield(CBO)inStuart McIntosh(CMO)inDavid Sutherland(VP Finance & Controller)
Co-investorsB Capital GroupB4 CapitalCambridge Innovation CapitalGV (Google Ventures)Lightstone VenturesRevelation Partners+1 more
.jpeg){kind=logo}
BiotechNewton Centre, US
Chaime Orlev(Executive Officer)Roni Mamluk(Executive Officer, Director)
BoardScott Minick(Director)inTodd T. Foley(Director)inVincent Miles(Director)Ansbert K. Gadicke(Director)in
Co-investorsHEALTHCARE ROYALTY PARTNERSSofinnova VenturesAbingworthMPM BioImpact
City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands.
BiotechMedical DevicesCambridge, US
Mark Keating, MD(Co-founder)Kotaro Nakanishi, PhD(Co-founder)Yukihide Tomari, PhD(Co-founder)Phillip Zamore, PhD(Co-founder)Andy Orth(Chief Executive Officer)in
Co-investorsAN Venture PartnersSofinnova VenturesCasdin CapitalFidelity InvestmentsInvusNYBC Ventures+2 more
Cambridge, MA clinical-stage biotech developing engineered exosome therapeutics; IPO'd on NASDAQ in 2020, later restructured.
BiotechSeattle, US
Doug Williams(Executive Officer, Director)in
BoardNoubar Afeyan(Director)inSteven Gillis(Director)Eric Lander(Director)
Co-investorsEcoR1 CapitalAlexandriaFidelity InvestmentsFlagship PioneeringQatar Investment Authority
Countable Labs (formerly Enumerix) develops Countable PCR, a DNA quantification technology that provides absolute target counts at single-molecule resolution as an alternative to qPCR, digital PCR, and NGS.
BiotechDeep TechHealthtechMedical DevicesPalo Alto, US
Stephen Fodor(Co-Founder & Board Director)Ari Chaney(Co-Founder & Board Director)inChristina Fan(Co-founder + CTO)inGiovanna Prout(Chief Executive Officer)in
Co-investorsF-Prime CapitalPrimer Ventures
Hong Kong-listed (HKEX: 2616) Chinese biopharmaceutical company developing oncology, immunology and inflammation therapies.
Co-investors6 Dimensions CapitalBoyu CapitalGICHillhouse CapitalWuXi Healthcare Ventures
Curie.Bio is a biotech venture firm pairing seed capital with in-house drug discovery support for therapeutics founders.
Zach Weinberg(Founder)in
Co-investorsAlleyCorpBoxGroupDNA CapitalF-Prime CapitalGV (Google Ventures)Lightstone Ventures+5 more
deCODE analyzes and interprets the human genome to identify genetic risk factors for common diseases including cardiovascular disease and cancer.
AI & Machine LearningBiotechDeep TechReykjavik, IS
Kári Stefánsson(CEO and founder of deCODE genetics)in
Dewpoint Innovations develops functional nanostructured polymeric surfaces for atmospheric water capture, technology originating from PhD research at the University of Sydney.
CleantechClimate TechDeep TechNew Materials
Chiara Neto(Founder & Advisor (Chief Scientific Officer))inMing Chiu(Founder & CTO)in
Co-investorsImpact Ventures Management Pty LtdPacific Channel3E Bioventures CapitalEcoR1 CapitalGeneral CatalystLeaps by Bayer+3 more
Dispatch Bio develops a universal immunotherapy treatment for solid tumors, combining engineered immunotherapy with a tumor-specific virus to improve cancer treatment outcomes.
BiotechDeep TechMedical Devices
Lex Johnson(Co-Founder and Chief Platform Officer)inRay Liu(Co-founder and Head of Synthetic Biology)Jeff Marrazzo(Founder)inSabah Oney(Chief Executive Officer)in
Co-investorsAlexandriaStanford University
Encoded develops gene therapies for neurological disorders through an integrated platform approach.
BiotechSouth San Francisco, US
Stephanie Tagliatela(Co-founder, Chief Scientific Officer & Board Member)inKartik Ramamoorthi, Ph.D.(Co-founder, Chief Executive Officer & Board Member)
Co-investorsBioBritGV (Google Ventures)Illumina VenturesMenlo VenturesSoftBank Vision FundVenrock+2 more
San Diego protein-sequencing company behind the ProteoCode platform; ceased operations in late 2025.
Co-investorsDecheng CapitalAlexandriaDeerfield Management CompanyGV (Google Ventures)Nan Fung Life SciencesNorthpond Ventures
Countable Labs (formerly Enumerix) develops a digital PCR platform that performs genetic analysis with higher sensitivity, precision, and dynamic range than legacy PCR methods.
AI & Machine LearningBiotechDeep TechMedical Devices
Develops novel ocular therapies.
BiotechMorrisville, US
Ben Yerxa(Executive Officer)inEric Linsley(Executive Officer)in
BoardEd Mathers(Director)inStephen Bloch(Director)inSeth Rudnick(Director)inNeal Fowler(Director)
Co-investorsCanaan PartnersNew Enterprise Associates (NEA)Pappas Capital+ND CapitalIllumina VenturesOMX Ventures
Epirium Bio develops novel oral therapeutics targeting mitochondrial dysfunction and muscle diseases, particularly muscular dystrophy.
BiotechMedical DevicesSan Diego, US
Pam Taub(M.D., FACC, Founder)Alan Maisel(M.D., Founder)Francisco Villarreal(M.D., Ph.D., Founder)Jonathan Taub(Co-founder and first Chief Executive Officer)Guillermo Ceballos(M.D., Founding Scientist)Pam Taub, M.D., FACC(Co-founder)
Co-investorsBluebird VenturesBroadview VenturesLongitude CapitalAdams Street PartnersVertex VenturesVertex Ventures HC
EQRx was a Cambridge, MA biopharma that aimed to sell lower-priced novel drugs; it was acquired by Revolution Medicines in 2023.
Co-investorsAndreessen HorowitzArboretum VenturesGV (Google Ventures)Nextech InvestBain CapitalCasdin Capital+1 more
Gate Bioscience develops small molecule therapeutics called Molecular Gates for disease treatment.
BiotechDeep TechMedical Devices
Jordi Mata-Fink(Chief Executive Officer, Co-Founder)inRaman Talwar(Chief Technology Officer, Co-Founder)inPat Sharp(Scientific Founder)in
Co-investorsForbionVersant VenturesAndreessen HorowitzFelicis VenturesGV (Google Ventures)
Cambridge, MA biotechnology company developing injectable synthetic biomarkers for noninvasive disease staging and treatment monitoring.
BiotechCambridge, US
Gabriel Kwong(Executive Officer)inSangeeta BhatiainRoopom Banerjee(Executive Officer)in
BoardTheresia Gouw(Director)inAmy Schulman(Director)Stan Lapidus(Director)in
Co-investorsGreatPoint VenturesAcrew CapitalAspect VenturesCatalio Capital ManagementCRV (Charles River Ventures)Dns Capital+7 more
Cambridge, MA biotech developing engineered tRNA "protein editing" therapeutics for nonsense-mutation diseases; reported shut down in 2025.
Cambridge, US
Leslie J Williams(Executive Officer, Director)
BoardBenjamin Chen(Director)Seiji Miyahara(Director)inSacha Mann(Director)David Moskowitz(Director)Steven Gillis(Director)in
Co-investors5AM Ventures8VCAtlas VenturePanacea VentureTaiho Ventures, LLCTakeda Ventures
Comofi Medtech develops healthcare technology, including an AI/AR-based surgical intervention platform for surgical procedures and an NT-Mask, aimed at improving patient outcomes and the safety and efficiency of healthcare practitioners.
AI & Machine LearningHealthtechMedical Devices
Co-investorsJITO Angel NetworkCIIE.COIIMA VenturesAbstract VenturesGeneral CatalystLightspeed Venture Partners
Butterfly Learnings provides developmental and behavioral therapy for children with autism, including speech and behavior support delivered by senior and behavior therapists.
Digital HealthHealthtechWellness & FitnessMumbai, IN
Co-investorsIIMA VenturesInsitorAbstract VenturesGeneral CatalystLightspeed Venture Partners
Biotech company developing antibodies to treat autoimmune and inflammatory diseases.
Co-investorsAlpha Wave GlobalArkin CapitalArkin Digital HealthJeito CapitalMonograph Capital PartnersViking Global Investors
HiberCell develops therapeutic candidates targeting the Integrated Stress Response pathway to address treatment-resistant cancers, relapse, and metastasis.
BiotechMedical Devices
Julio Aguirre-Ghiso, Ph.D.(Co-Founder)
Co-investorsMagnetic VenturesRaptor Group6 Dimensions CapitalHercules Capital, Inc.Hillhouse Capital
Homeward provides cash offers for home purchases, allowing buyers to make competitive offers without financing contingencies while enabling real estate agents to maintain full commissions.
FintechPropTechAustin, US
Jeff Diehl(Director)Jeffrey Crowe(Director)Srini Palamarthy(Executive Officer)Ben Rubenstein(Director)
BoardTim Heyl(Executive Officer, Director)inKrishna Srinivasan(Director)in
Co-investorsBreyer CapitalEra VenturesHarmony PartnersJavelin Venture PartnersLiveOak VenturesNorwest Venture Partners+3 more
Homeward Health provides in-home and virtual primary care and care coordination services for Medicare Advantage patients, helping with appointment scheduling, health advocacy, insurance navigation, and access to community resources.
Digital HealthHealthtech
Co-investorsGeneral CatalystHuman Capital
Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.
BiotechBedford, US
Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)
BoardSteven Gillis(Director)Arthur Tzianabos(Executive Officer, Director)Kush Parmar(Director)inRichard Gregory(Director)
Co-investors5AM VenturesOUP (Osage University Partners)AlexandriaDeerfield Management CompanyFidelity InvestmentsHBM Healthcare Investments+5 more
Shanghai-based, HKEX-listed drug developer commercializing dorzagliatin, the first approved glucokinase activator for type 2 diabetes.
Co-investorsF-Prime CapitalVenrock6 Dimensions CapitalAlly Bridge GroupBlue Pool CapitalEight Roads Ventures+2 more
Scalable, high throughput DNA sequencing platforms.
Co-investorsArtis VenturesHemisphere Ventures LLCHeran PartnersSPRINGROCK VENTURESVenrockGenesys Capital
ImmusanT works on scientific research into the mechanisms of celiac disease, collaborating with investigators from academic and medical research institutions.
BiotechHealthtechCambridge, US
Leslie Williams(Executive Officer, Director)Thomas Daniel(Director)Steven Gillis(Director)Thomas Koestler(Director)
BoardCeclia Gonzalo(Director)Kevin Ferro(Director)
Co-investorsVatera Healthcare Partners
Jaguar Gene Therapy develops gene therapy treatments for severe genetic diseases, focusing on AAV-based platform therapies designed to deliver one-time, long-lasting treatments.
BiotechHealthtechMedical DevicesLake Forest, US
Joseph NolaninJoe Nolan, MBA(Chief Executive Officer)
Co-investorsAIFJDRF T1D FundDeerfield Management CompanyGoldman SachsSamsung Ventures
Just - Evotec Biologics is a contract development and manufacturing organization (CDMO) providing antibody discovery, process development, and cGMP manufacturing services for antibodies, next-generation biologics, and biosimilars.
Advanced ManufacturingBiotechHealthtechSeattle, US
A biopharmaceutical company developing CAR-T cell therapies for cancer treatment.
BiotechHealthtechMedical DevicesShanghai, CN
Co-investorsAcorn Pacific VenturesYuanBio Venture CapitalShiyu CapitalTemasek
Karuna Therapeutics is a Boston neuroscience biopharma behind muscarinic drug KarXT, acquired by Bristol Myers Squibb in 2024.
Co-investorsPivotal Life SciencesSofinnova VenturesAlexandriaPureTech HealthWellcome Trust
KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Tim Wang(Cofounder)JOHN TRZUPEK, PH.D.(TREASURER, SECRETARY & CHIEF FINANCIAL OFFICER)DAVID P. MEEKER, M.D.(PRESIDENT AND CHIEF EXECUTIVE OFFICER)inFRANK STEGMEIER, PH.D.(CHIEF SCIENTIFIC OFFICER)Qasim Rizvi(Chief Executive Officer)inJAMES GILBERT(Director)
Co-investorsAlpha Wave GlobalFlagship PioneeringLAVLG Technology VenturesLilly Asia VenturesBaillie Gifford+3 more
Aesthetic-medicine biopharma behind KYBELLA (deoxycholic acid) injection, acquired by Allergan in 2015 for ~$2.1 billion.
Co-investorsAisling CapitalMESA VERDE VENTURE PARTNERSProspect Venture PartnersSchooner CapitalALTITUDE LIFE SCIENCE VENTURESFoley Ventures+1 more
LifeMine is a biopharmaceutical company that uses data science and advanced methods to accelerate drug discovery and develop precision medicines across therapeutic areas.
AI & Machine LearningBiotechDeep TechCambridge, US
Gregory L. Verdine(Executive Officer, Director)Gregory Verdine, Ph.D.
BoardHingge Hsu(Executive Officer, Director)Weiqing Zhou(Executive Officer, Director)
Co-investorsGV (Google Ventures)RA CapitalAisling CapitalAlexandriaBezos ExpeditionsBlue Pool Capital+7 more
Lightcast develops a single-cell functional analysis platform that uses droplet-based technology to profile cell function, biomolecule secretion, cell-cell interactions, and targeted cell killing at scale.
BiotechDeep TechHealthtech
Co-investors+ND CapitalIllumina VenturesLongwall Venture Partners LLPM VenturesOMX Ventures
Lightcast provides a next-generation single-cell functional analysis platform called Envisia that enables massively parallel profiling of cell-cell interactions and biomolecule secretion at scale.
BiotechDeep TechMedical DevicesCambridge, GB
Co-investorsIllumina VenturesPerscitus LLP+ND CapitalM VenturesOMX Ventures
San Diego, US
Bob Kain(Executive Officer, Director)inDawn Barry(Executive Officer)inJoseph C. Beery(Executive Officer, Director)
Co-investorsBain Capital VenturesF-Prime CapitalIllumina VenturesOsage University Partners
Lyell develops CAR T-cell therapies for cancer patients by leveraging deep expertise in T-cell biology and oncology.
BiotechDeep TechHealthtechMedical DevicesBothell, US
Stan Riddell(Executive Officer)Richard Klausner(Executive Officer, Director, Promoter)Stephen Hill(Executive Officer)inHeather Turner(Executive Officer)inRichard Goold(Executive Officer)inMargo Roberts(Executive Officer)
Co-investorsForesite CapitalvenBio Partners8VCAxial VC
Lyell Immunopharma is a Nasdaq-listed cell therapy developer engineering T cell therapies for solid tumors and blood cancers.
Following a 2025 merger of Mallinckrodt and Endo, the combined business separated into two companies: Keenova Therapeutics, which develops treatments for rare, stigmatized, or unaddressed conditions across areas such as immunology, urology, hepatology, ophthalmology, orthopedics, and critical care; and Par Health, which produces generics, sterile injectables, and active pharmaceutical ingredients backed by a U.S.-based manufacturing network.
Advanced ManufacturingBiotechHealthtechMedical Devices
Co-investorsCross Creek AdvisorsPfizer Venture InvestmentsSignet Healthcare PartnersSofinnova Ventures
A manufacturing company focused on domestic production of robotics, aiming to build large-scale factories and apply AI in manufacturing.
Advanced ManufacturingAI & Machine LearningRobotics
Co-investorsScribble VenturesThe Westly GroupCollaborative FundExor Ventures
Matter is a read-later app for iPhone, iPad, and web that saves articles, newsletters, threads, PDFs, and video/podcast content with parsing and search capabilities.
ConsumerMedia & EntertainmentSaaSSan Francisco, US
Ben Springwater(Founder)inRobert Mackenzie(Founder)in
Co-investorsAdapt VenturesGV (Google Ventures)Outliers VCY CombinatorAndreessen HorowitzCollaborative Fund+12 more
Matter develops a consumer iOS app that helps users track positive emotions and brain activity to improve subjective well-being.
AI & Machine LearningConsumerHealthtechMental HealthWellness & Fitness
Axel Bouchon(Founder)inBen Goldhirsh(Co-founder)inChris Shiflett(Co-founder)in
Co-investorsCollaborative FundExor VenturesPolaris Partners
Maze is a security company, founded in 2024, that uses AI to help defenders identify and address vulnerabilities in code and cloud environments.
AI & Machine LearningCloud ComputingCybersecurityDeveloper Tools
Co-investorsTapestry VCTheory Ventures
MindImmune develops therapeutics targeting the immune drivers of neurodegenerative diseases such as Alzheimer's, focusing on immune cells that respond to amyloid plaques before they enter the brain.
BiotechHealthtechKingston, US
Robert B. Nelson(Executive Officer, Director)Frank S. Menniti(Executive Officer, Director)inStevin Zorn(Executive Officer, Director)inIsaac Stoner(CEO)in
BoardRichard G. Horan(Director)Reetika Bhardwaj(Director)in
Co-investorsDolby Family VenturesPfizer Venture InvestmentsSlater Technology FundPfizer Ventures
Mirador provides digital lending platform software for financial institutions, credit unions, and banks to streamline online loan applications.
Cloud ComputingEnterprise SoftwareFintechSaaS
Co-investorsCore Venture CapitalNycaNyca PartnersFidelity InvestmentsInvusOrbiMed+3 more
Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.
BiotechMedical Devices
Mark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)Calvin Kuo(Scientific Co-Founder)Katie Fanning(President & Chief Executive Officer)in
Co-investorsJDRF T1D FundMRL Ventures FundOno Venture Investment, Inc.Pfizer Venture InvestmentsSofinnova PartnersAlexandria+4 more
CREATE Medicines develops in vivo CAR immunotherapy using proprietary mRNA-LNP technology to program T cells, NK cells, and myeloid cells directly within the body for cancer, autoimmunity, and fibrosis.
AI & Machine LearningBiotechHealthtechMedical DevicesCambridge, US
Daniel Getts, Ph.D.(Chief Executive Officer, Cofounder, Board Director)
Co-investors8VCAlexandriaHatteras Venture PartnersNewpath Partners
nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.
BiotechDeep TechMedical DevicesBoston, US
Luke Gilbert, PhD(Founder)Keith Joung, MD, PhD(Founder)David Liu, PhD(Founder)Angelo Lombardo, PhD(Founder)Luigi Naldini, MD, PhD(Founder)Jonathan Weissman, PhD
Co-investorsAtlas VentureNewpath Partners5AM VenturesDCVC (Data Collective)F-Prime CapitalGV (Google Ventures)+11 more
Nebula is a cloud gaming service that lets users stream over 1,000 games instantly on Windows, MacOS, and Android without downloads or installations.
Cloud ComputingConsumerGamingMountain View, US
Gordon Stitt(Executive Officer, Director)Devin Carlen(Director)Chris C. Kemp(Executive Officer, Director)
BoardLouis Toth(Director)inMark Leslie(Director)Peter Bell(Director)
Co-investorsAlpha Startups Pre-AcceleratorComcast VenturesF-Prime CapitalFenbushi CapitalHemi Ventures, LlcHighland Capital Partners+5 more
Nebula Genomics offers whole genome sequencing, providing consumers with health, trait, ancestry, and oral microbiome reports based on 100% of their DNA.
BiotechConsumerDigital Health
George Church(Founder)in
Co-investorsF-Prime CapitalHemi Ventures, LlcHikma VenturesWindham Capital PartnersFenbushi CapitalKhosla Ventures+1 more
Nimbus Therapeutics is a biotechnology company that designs precision small molecule medicines using a computational, multidisciplinary drug discovery approach.
AI & Machine LearningBiotechDeep TechHealthtech
Co-investorsAccess BiotechnologyAtlas VentureBain Capital Life SciencesDementia Discovery FundGV (Google Ventures)Lightstone Ventures+4 more
San Diego DNA sequencing company behind the Sequencing by Binding short-read platform; acquired by Pacific Biosciences in 2021.
BiotechSan Diego, US
David S. Mullarkey(Executive Officer, Director)Arnold Oliphant(Executive Officer)inKen Song, M.D., Ph.D.(Executive Officer, Director)Kelly Perez(Executive Officer)John Murphy, Ph.D.(Executive Officer)Millard Y Chan(Chief Operating Officer, Secretary and Director)
Co-investorsATEL VenturesDCVC (Data Collective)Decheng CapitalLam CapitalPivotal Life SciencesALTITUDE LIFE SCIENCE VENTURES+3 more
Singapore A*STAR spin-off building automated nucleic acid extraction and silicon-photonics point-of-care molecular diagnostics.
ONI develops the Nanoimager, an automated super-resolution imaging system.
BiotechDeep TechHardwareMedical DevicesOxford, GB
Co-investorsAnjostArtis VenturesFuture Planet CapitalOxford Technology ManagementVertical Venture PartnersAxon Ventures+6 more
Oratomic builds fault-tolerant quantum computers using ultra-efficient error correction with light and atoms.
AI & Machine LearningDeep TechQuantum Computing
Dolev BluvsteininMadelyn Cainin
BoardJohn Preskill
Co-investorsBain Capital VenturesGeneral CatalystIndex VenturesKhosla VenturesSpark CapitalBezos Expeditions+3 more
A pharmaceutical company developing therapeutics across oncology, hematology, neuroscience, immunology, and cardiovascular disease with a pipeline of 50 compounds targeting 40+ disease areas.
BiotechHealthtechMedical Devices
Co-investorsAndreessen HorowitziGlobe PartnersAgent CapitalAlexandriaCasdin CapitalInvus+2 more
Paradigm Health is an Indiana-based hospice and palliative care provider offering community-based, holistic care to patients and support for their families and caregivers.
Digital HealthHealthtechWellness & Fitness
Jeff Jarecki(Founder & Chairman)in
Co-investorsCressey & CompanyHavencrest Capital ManagementF-Prime CapitalGeneral CatalystGV (Google Ventures)Lux Capital+1 more
Paratus Sciences is a drug discovery company that uses AI-powered methods to identify first-in-class medicines by studying evolutionary traits, targeting serious diseases where current therapies are inadequate.
AI & Machine LearningBiotechDeep TechUnited States, US
Co-investorsClavystBioEcoR1 CapitalLeaps by Bayer
Moonwalk Biosciences is a life sciences company operating in the biotech sector.
AI & Machine LearningBiotechDeep TechHealthtechSouth San Francisco, US
Arash Jamshidi(Co-Founder, President & CTO)inAlex Aravanis(Co-Founder & CEO)in
Co-investorsAlpha Wave GlobalKhosla VenturesFuture VenturesGV (Google Ventures)YK Bioventures
Prometheus Fuels develops systems that convert intermittent renewable energy into liquid fuels for remote electrification.
Advanced ManufacturingCleantechClimate TechDeep TechEnergySanta Cruz, US
Rob McGinnis(Founder/CEO)in
Co-investorsBMW i VenturesEmles Venture PartnersExpaMaersk GrowthMetaplanetY Combinator+10 more
Protillion Biosciences develops platform technology for antibody engineering and drug discovery.
AI & Machine LearningBiotechDeep TechCarlsbad, US
Curtis Layton(CEO/Co-Founder)inDavid Walt(Co-Founder)inWill Greenleaf(Co-Founder)inRobert Hollingsworth(Chief Scientific Officer)in
BoardSean Kendall(Director)inMalek Faham(Director)in
Co-investorsIllumina VenturesMerck Global Health Innovation FundMSD Global Health Innovation Fund
Hangzhou-based gene-editing biotech developing immune-privileged cell therapies and xenogeneic organs for transplant and cancer.
Hangzhou, CN
Luhan Yang, PhD(Co-Founder and Chief Executive Officer)George Church, PhD(Co-founder and Co-Chair of Qihan scientific advisory groups)
Co-investorsAlta PartnersLAVSequoia Capital
Quantum Circuits develops superconducting quantum computers using dual-rail qubits with built-in error detection, designed to accelerate the path to fault-tolerant quantum computing.
Advanced ManufacturingDeep TechHardwareQuantum ComputingMadison, US
Rob Schoelkopf(Sterling Professor, Founder)inLuigi FrunzioRay Smetsin
Co-investorsCanaan PartnersConnecticut InnovationsF-Prime CapitalFitz Gate VenturesOUP (Osage University Partners)Sequoia Capital+1 more
Reactive Biosciences is a drug discovery company applying a boron-based chemistry platform to develop new medicines.
Co-investorsCanaan Partners
San Diego biopharmaceutical company developing GPCR-targeted immune-inflammatory drugs; acquired by Celgene for ~$7.2B in 2015.
BiotechSan Diego, US
Marcus Boehm(Executive Officer)inRobert Peach(Executive Officer)inRaymond Stevens(Director)inFaheem Hasnain(Executive Officer, Director)inJames Schmidt(Executive Officer)inChrysa Mineo(Executive Officer)in
Co-investorsOUP (Osage University Partners)Ridgeback CapitalVenrockLilly Ventures
Recuro is a virtual-first digital health platform that provides primary care, behavioral health, urgent care, and supplemental benefits (pharmacy, care management, advocacy) to patients, employers, health plans, and providers.
Digital HealthHealthtechSaaSRichardson, US
Michael Brombach(Chief Executive Officer and Co-Founder)inMichael Gorton(Chief Executive Officer)inDr. Kate Sowerwine(Chief Medical Officer)John Halsey(Director)Kris Engskov(Director)inWilliam Paiva(Director)
Co-investors1843 Capital4D CapitalCortado VenturesCure VenturesGlobal Insurance AcceleratorMighty Capital+4 more
Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.
AI & Machine LearningBiotechWatertown, US
Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)inRobert Gagnon(Executive Officer)Heather Wasserman(Executive Officer)inMatthew Patterson(Director)inScott Biller(Director)in
Co-investorsAtlas VentureForesite CapitalThe Column GroupDecheng Capital
Kissht is a technology-enabled digital lender in India offering personal loans up to ₹5 lakh and loans against property up to ₹30 lakh through its mobile application.
AI & Machine LearningFintechInsurTechMumbai, IN
Ranvir Singh(Chairman and Chief Executive Officer, Founder and Promoter)inKrishnan Vishwanathan(Founder and Promoter)
Co-investorsTrifecta Capital AdvisorsSnowflake Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Apex Neuro Holdings, Inc.BoragenEncentrio Therapeutics, Inc.High Plains Partners, LLCLyceraOctave Bioscience IncOllin Biosciences, Inc.Sapphire EnergyTrelysAlly TherapeuticsApoGen BiotechnologiesAstromechAvila TherapeuticsBIND TherapeuticsBitterroot BioCardero TherapeuticsDispatch BioElephasHappy HealthHuman Immunology BiosciencesInograft BiotherapeuticsInterline TherapeuticsKaizen Brain CenterLilac TherapeuticsLodo TherapeuticsMagnolia NeurosciencesMoonwalk BiosciencesNitronexNohla TherapeuticsPetra PharmaRodeo Therapeutics
Browse all 231 investments with full details →
▶31 more tracked companies
ROME TherapeuticsSage TherapeuticsSagerxScale BiosciencesSciNeuroSciNeuro PharmaceuticalsSemma TherapeuticsSingleron BiotechnologiesSingular Genomics SystemsSironaxSonomaSonoma BiotherapeuticsSorbent TherapeuticsSunBird BioSynchronSyndexThermo Fisher ScientificTome BiosciencesTranscenta HoldingTranscripta BioTraseTrase SystemsTrotana TherapeuticsUltraDx BioVBI VaccinesVerve TherapeuticsVesalius TherapeuticsVilyaVolastraWalden BiosciencesXaira Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 71
38 IPOs · 33 acquisitions · showing 31Prime MedicineNASDAQ: PRME908 DevicesNASDAQ: MASSBeam TherapeuticsNASDAQ: BEAMBoundless BioNASDAQ: BOLDEnliven TherapeuticsNASDAQ: ELVNGossamer BioNASDAQ: GOSSGrailNASDAQ: GRALNeumora TherapeuticsNASDAQ: NMRAQuanterixNASDAQ: QTRXScholar RockNASDAQ: SRRKScholar Rock Holding Corp, Inc.NASDAQ: SRRKSeaport TherapeuticsNASDAQ: SPTXTwist BioscienceNASDAQ: TWSTVirNASDAQ: VIRVoyager Therapeutics, Inc.NASDAQ: VYGRAgios PharmaceuticalsNASDAQ: AGIOAlnylam PharmaceuticalsNASDAQ: ALNYDenali TherapeuticsNASDAQ: DNLIErascaNASDAQ: ERASGenerate BiomedicinesNASDAQ: GENBKardiganNASDAQ: KARDKura OncologyNASDAQ: KURAMaze TherapeuticsNASDAQ: MAZEParabilis MedicinesNASDAQ: PBLSPerkinelmerNYSE: RVTYPulmatrixNASDAQ: PULMRapport TherapeuticsNASDAQ: RAPPMetseraacq. by PfizerVividion Therapeuticsacq. by BayerHI-Bioacq. by BiogenJUST Biotherapeuticsacq. by Evotec
Portfolio news
latest coverage across their companies
LifeMine Therapeutics · finsmes.com · Aug 8, 2026
Vir · biospace.com · Aug 6, 2026
Transcripta Bio · finsmes.com · Jul 23, 2026
Trase · finance.yahoo.com · Jun 25, 2026
SonoThera · finsmes.com · Jun 10, 2026
Fund performance · per public LP disclosures · 6
as of Dec 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| ARCH VENTURE FUND XIII LPLPs: Texas Municipal Retirement System, Carnegie Corporation of New York, University of Texas Investment Management Company | 2023 | — | 39.8% | 1.25x | 0.00x |
| Arch IX OverageLPs: North Carolina Retirement Systems | 2016 | — | 26.0% | 2.85x | 1.89x |
| ARCH VENTURE FUND VI LPLPs: California State Teachers' Retirement System, The Regents of the University of California, Ewing Marion Kauffman Foundation +1 more | 2003 | — | 2.4% | 1.24x | 1.24x |
| ARCH VENTURE FUND IX LPLPs: North Carolina Retirement Systems, University of Texas Investment Management Company | — | — | 24.2% | 2.58x | 1.53x |
| ARCH VENTURE FUND VII LPLPs: North Carolina Retirement Systems, The Regents of the University of California, University of Texas Investment Management Company | — | — | 37.8% | 4.83x | 4.60x |
| ARCH VENTURE FUND VIII LPLPs: North Carolina Retirement Systems, University of Texas Investment Management Company | — | — | 21.6% | 3.19x | 2.44x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
IPO stake values · per SEC filings · 11
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Vir | 25.2% | $20.00 | Oct 2019 | $553.3M |
| Neumora Therapeutics | 18.4% | $17.00 | Sep 2023 | $476.8M |
| Prime Medicine | 12.0% | $17.00 | Oct 2022 | $194.8M |
| Beam Therapeutics | 14.5% | $23.50 | Oct 2020 | $193.7M |
| Erasca | 9.4% | $16.00 | Jul 2021 | $176.9M |
| Gossamer Bio | 12.7% | $16.00 | Feb 2019 | $128.9M |
| Parabilis Medicines | 5.4% | $20.00 | Jun 2026 | $128.3M |
| Seaport Therapeutics | 9.8% | $18.00 | May 2026 | $93.5M |
| Maze Therapeutics | 9.4% | $16.00 | Jan 2025 | $65.9M |
| Rapport Therapeutics | 10.5% | $17.00 | Jun 2024 | $63.4M |
| Boundless Bio | 11.2% | $16.00 | Mar 2024 | $39.9M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Public market activity · per SEC filings
what is this? ⓘ10 insider ownership filings (Forms 3/4/5)
at Kardigan, Inc. (KARD), Lyell Immunopharma, Inc. (LYEL), Metsera, Inc. (MTSR)
Files 13F institutional holdings reports · latest Aug 2026
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has ARCH Venture Partners made?
- ARCH Venture Partners has 231 tracked investments, 71 of which have exited, including 40 dated in the last 24 months.
- What stage does ARCH Venture Partners invest at?
- ARCH Venture Partners invests at the Seed, Series A, Series B, Series C, Growth stages.
- What is ARCH Venture Partners's typical check size?
- ARCH Venture Partners typically writes checks of $50K – $250M.
- What sectors does ARCH Venture Partners focus on?
- ARCH Venture Partners focuses on AI & Machine Learning, Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices, Quantum Computing.
- Where is ARCH Venture Partners located?
- ARCH Venture Partners is headquartered in Chicago, US.
- Does ARCH Venture Partners lead rounds?
- ARCH Venture Partners typically participates in rounds rather than leading them.
- Who does ARCH Venture Partners co-invest with?
- ARCH Venture Partners most often shares deals with GV (Google Ventures), F-Prime Capital, Foresite Capital, among 218 tracked co-investors.
Media · Podcasts & interviews
featuring the teamARCH Venture's Kristina Burow on Investing in "Truly Transformative" Science
Falk Marques Group: Interviews With Women in Private Equity · Kristina Burow
Steven Gillis, PhD | Managing Director | ARCH Venture Partners
Life Science Washington · Steven Gillis
Images
Co-investors · 96
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.
Venrock is a venture capital firm investing across technology and healthcare, backing companies in fintech, developer infrastructure, life sciences, therapeutics, semiconductors, and consumer products.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
General Catalyst is a venture capital firm operating as a partnership focused on company building and accelerating the growth of the businesses it backs.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.
Samsara BioCapital is a life-sciences investment firm backing companies developing transformative therapeutics for patients.
Third Rock Ventures is a venture capital firm that discovers, launches, and builds life sciences and biotechnology companies developing novel medicines and therapies.
6 Dimensions Capital is a healthcare-focused investment firm with offices in Boston, San Francisco, Hong Kong, and Shanghai. It backs healthcare startups and growth-stage companies operating in the U.S., Europe, China, Israel, and other markets, with an emphasis on life sciences businesses spanning China and the United States.
▶84 more co-investors
SoftBank Vision FundAtlas Venture5AM VenturesFlagship PioneeringSofinnova VenturesLeaps by Bayer+ND CapitalNew Enterprise Associates (NEA)Canaan PartnersNextech InvestCatalio Capital Management, LPMenlo VenturesLux CapitalNorthpond VenturesDeerfield Management CompanyM VenturesAlumni VenturesS32In-Q-TelCatalio Capital ManagementVertex Ventures HCSequoia CapitalJohnson & Johnson Innovation – JJDCDomain AssociatesFrazier Healthcare PartnersBain Capital Life SciencesLightspeed Venture PartnersInsight PartnersSignalFireVersant VenturesFoothill VenturesSR One Capital ManagementForbionVida VenturesMedical Excellence CapitalCraft VenturesCoatue ManagementInnovation EndeavorsTwo Sigma VenturesArtis VenturesPaladin Capital GroupSofinnova PartnersMPM BioImpactCambridge Innovation CapitalThe Column GroupAbingworthRazor's Edge VenturesMatrix Capital ManagementMadrona Venture GroupFoundryParadigm23andMeFormation GroupAmino CapitalIlluminate VenturesArrive7wire VenturesAdvent Life SciencesVertical Venture PartnersHealthCapCure VenturesCortado VenturesNotable CapitalUnknown VenturesAtomicoGreycroftMaveronKortschak Investments L.P.Entrepreneur FirstLOI VentureBaruch Future VenturesIncisive VenturesStrawberry Creek VenturesEQT Life SciencesTA VenturesNeotribe VenturesPitbull VenturesAt One VenturesWave Digital AssetsWaverley CapitalAndera PartnersDFJAltitude Ventures Management, LlcGENERAL INCEPTION
Firms observed investing alongside ARCH Venture Partners, from public investor directories. Shared companies are the overlap with ARCH Venture Partners's recorded portfolio.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
Olive Tree Capital is a venture capital firm that invests in founders building at the technological frontier.
Kyoto University Innovation Capital (Kyoto iCAP) is a venture capital firm wholly owned by Kyoto University, established in December 2014 to commercialize research and technology developed by the university's researchers.